中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2015年
16期
49-49,58
,共2页
盛波%杨振华%黄力建%刘方颖%龙建安%李叶枚%商健彪
盛波%楊振華%黃力建%劉方穎%龍建安%李葉枚%商健彪
성파%양진화%황력건%류방영%룡건안%리협매%상건표
肝癌%化疗栓塞%介入手术%外科手术
肝癌%化療栓塞%介入手術%外科手術
간암%화료전새%개입수술%외과수술
Liver carcinoma%Chemoembolization%Interventional operation%Surgical operation
目的:探讨经皮肝动脉化疗栓塞术(TACE)治疗后联合二期手术切除治疗BCLC-B期肝癌的意义。方法以TACE处理已丧失手术切除机会的BCLC-B期肝癌患者,有33例患者肿瘤缩小后获得二期手术切除肿瘤的机会,随访并分析其术后并发症,复发以及远期生存情况。结果33例中18例患者待手术时肿瘤缩小50%以上,15例待手术时肿瘤缩小30%~50%。联合二期手术切除术后1、3、5年生存率为83.6%、51.2%、34.7%,中位生存期39个月。结论 TACE并二期手术切除对提高BCLC-B期肝癌远期生存率具有一定的价值,是临床值得应用的治疗方法。
目的:探討經皮肝動脈化療栓塞術(TACE)治療後聯閤二期手術切除治療BCLC-B期肝癌的意義。方法以TACE處理已喪失手術切除機會的BCLC-B期肝癌患者,有33例患者腫瘤縮小後穫得二期手術切除腫瘤的機會,隨訪併分析其術後併髮癥,複髮以及遠期生存情況。結果33例中18例患者待手術時腫瘤縮小50%以上,15例待手術時腫瘤縮小30%~50%。聯閤二期手術切除術後1、3、5年生存率為83.6%、51.2%、34.7%,中位生存期39箇月。結論 TACE併二期手術切除對提高BCLC-B期肝癌遠期生存率具有一定的價值,是臨床值得應用的治療方法。
목적:탐토경피간동맥화료전새술(TACE)치료후연합이기수술절제치료BCLC-B기간암적의의。방법이TACE처리이상실수술절제궤회적BCLC-B기간암환자,유33례환자종류축소후획득이기수술절제종류적궤회,수방병분석기술후병발증,복발이급원기생존정황。결과33례중18례환자대수술시종류축소50%이상,15례대수술시종류축소30%~50%。연합이기수술절제술후1、3、5년생존솔위83.6%、51.2%、34.7%,중위생존기39개월。결론 TACE병이기수술절제대제고BCLC-B기간암원기생존솔구유일정적개치,시림상치득응용적치료방법。
Objective To study the value of percutaneous transcatheter hepatic artery chemoembolization (TACE) in the treatment of stage BCLC-B hepatocellular carcinomaafter operation excision combined with second-stage operation. Methods The patients with HCC in stage BCLC-B who had lost the opporunity of surgical therapy been given TACE treatment.33 patients whose tumor shrink than before had the opportunity to have two stage operation. Follow-up and analysis of the postoperative complications,recurrence and long-term survival. Results In 18 patients of 30 patients participated in the experiment the tumor volume decreased more than 50%before operation.In the other 15 patients before operation the tumor volume was reduced from 30%to 50%. Combined with two postoperatively, 1, 3, 5 year survival rate was 83.6%, 51.2%and 34.7%, the median survival time was 39 months. Conclusion Combined two stage after TACE operation has certain value to improve the long-term survival rate of stage BCLC-B hepatocellular carcinoma, treatment method is worth of clinical application.